Supplemental material

Plasma biomarkers of neurodegeneration in patients with Parkinson's disease and

dementia with Lewy bodies and at-risk individuals of Lewy body disease in the NaT-

**PROBE** cohort

Keita Hiraga MD, Makoto Hattori, MD, PhD, Yuki Satake MD, Daigo Tamakoshi MD, Taiki

Fukushima MD, Takashi Uematsu, MD, Takashi Tsuboi, MD, PhD, Maki Sato, Katsunori

Yokoi, MD, PhD, Keisuke Suzuki, MD, PhD, Yutaka Arahata, MD, PhD, Yukihiko Washimi,

MD, PhD, Akihiro Hori, MD, PhD, Masayuki Yamamoto, MD, PhD, Hideaki Shimizu, MD,

PhD, Masakazu Wakai, MD, PhD, Harutsugu Tatebe, PhD, Takahiko Tokuda, MD, PhD,

Akinori Nakamura, MD, PhD, Shumpei Niida, PhD, Masahisa Katsuno, MD, PhD

**Contents:** 

Supplementary Table: 1

Supplementary Figures: 3

## Supplementary Table 1. Background characteristics of the patients with Parkinson's disease by cognitive function

	PD-CN	PD-CI	p value
Number (M:F)	40 (22:18)	44 (22:22)	0.668a
Age, years	64.4 (9.0)	72.8 (7.8)	<0.001 <sup>b</sup>
Education, years	13.6 (2.4)	12.9 (3.5)	0.284 <sup>b</sup>
DaT abnormal, %	23/23 (100)	20/20 (100)	$1.000^{a}$
MIBG abnormal, %	21/26 (80.8)	20/22 (90.9)	0.429 <sup>a</sup>
DaT and/or MIBG abnormal, %	33/33 (100)	29/29 (100)	$1.000^{a}$
Disease duration, years	6.3 (5.0)	5.5 (4.9)	0.582°
MoCA-J	27.6 (1.3)	21.7 (3.5)	<0.001°
Stroop test part 2 - part 1, sec	12.8 (7.5)	30.0 (45.2)*	0.062°
Line orientation test	17.2 (2.1)	14.5 (3.0)	<0.001°
Hoehn and Yahr	1.9 (0.8)	2.3 (1.0)	0.222°
LEDD	423.6 (449.6)	384.3 (327.1)	0.654°
MDS-UPDRS III	22.6 (9.8)	27.2 (10.3)	0.121°
Rigidity	3.2 (2.5)	3.9 (3.5)	0.701°
Tremor	3.6 (4.0)	3.9 (4.4)	0.754°
Bradykinesia	11.8 (5.4)	13.2 (5.7)	0.093°
Axial signs	4.0 (3.4)	6.2 (3.8)	$0.074^{\circ}$
SCOPA-AUT	10.5 (7.0)	12.5 (9.4)	$0.077^{\rm c}$
SAOQ, %	65.1 (38.3)	70.4 (35.1)	0.343°
RBDSQ	3.3 (2.1)	4.6 (3.2)	0.034°
BDI-II	8.8 (5.8)	10.7 (6.8)	0.045°
ESS	8.0 (4.6)	7.8 (5.1)	0.205°
PDQ-39 summary index	15.8 (11.5)	22.7 (17.9)	$0.005^{c}$
QUIP	0.3 (0.8)	0.5 (1.0)	0.038°

Patients with PD with MoCA-J ≥26 and <26 are classified as cognitively normal (PD-CN) and cognitively impaired (PD-CI), respectively

PD, Parkinson's disease; DaT, dopamine transporter; MIBG, metaiodobenzylguanidine; MoCA-J, the Japanese version of the Montreal Cognitive Assessment; LEDD, Levodopa equivalent daily dose; MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; SCOPA-AUT, the Japanese version of the Scale for Outcomes in Parkinson's disease for Autonomic Symptoms; SAOQ, Self-administered Odor Question; RBDSQ, RBD screening scale; BDI-II, Beck Depression Inventory-Second

Edition; ESS, Epworth Sleepiness Scale; PDQ-39, Parkinson's Disease Questionnaire-39; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease


\*Two patients with PD patients could not complete the Stroop test

<sup>a</sup>p values determined by Fisher's exact test

<sup>b</sup>p values determined by Student's *t*-test

<sup>c</sup>p values determined by analysis of covariance (ANCOVA) adjusted for age and sex

Data represent the mean (standard deviation) or value (%)




Supplementary Figure 1. Pearson's correlation between plasma biomarkers and age

Pearson's correlation test between plasma biomarkers and age in the low-risk group (A), high-risk group (B), Parkinson's disease group (C), and dementia with Lewy bodies group (D). The

cut-off values for A $\beta$  composite,  $\log_{10}$  (p-tau181), and  $\log_{10}$  (NfL) are indicated by dotted lines (A $\beta$  composite, 0.376;  $\log_{10}$  (p-tau181), 0.374;  $\log_{10}$  (NfL), 1.65).


 $A\beta$  composite, combination biomarker of amyloid-beta precursor protein (APP)<sub>669-711</sub>/amyloid-beta ( $A\beta$ )<sub>1-42</sub> and  $A\beta$ <sub>1-40</sub>/ $A\beta$ <sub>1-42</sub> ratios; p-tau181, phosphorylated tau 181; NfL, neurofilament light chain; aSyn/Hb, alpha-synuclein/hemoglobin ratio



## Supplementary Figure 2. Age-adjusted partial correlation between plasma biomarkers and clinical indices in patients with Parkinson's disease

Age-adjusted Pearson's partial correlation test between plasma biomarkers and clinical indices in the Parkinson's disease group.

Aβ composite, combination biomarker of amyloid-beta precursor protein (APP)<sub>669-711</sub>/amyloid-beta (Aβ)<sub>1-42</sub> and Aβ<sub>1-40</sub>/Aβ<sub>1-42</sub> ratios; p-tau181, phosphorylated tau 181; NfL, neurofilament light chain; aSyn/Hb, alpha-synuclein/hemoglobin ratio; MoCA-J, the Japanese version of the Montreal Cognitive Assessment; UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; SCOPA-AUT, the Japanese version of the Scale for Outcomes in Parkinson's disease for Autonomic Symptoms; SAOQ, Self-administered Odor Question; RBDSQ, RBD screening scale; BDI-II, Beck Depression Inventory-Second Edition; ESS, Epworth Sleepiness Scale; PDQ-39, Parkinson's Disease Questionnaire-39; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease



## Supplementary Figure 3. Age-adjusted partial correlation between plasma biomarkers and clinical indices in high-risk individuals

Age-adjusted Pearson's partial correlation test between plasma biomarkers and clinical indices in the high-risk group.

Aβ composite, combination biomarker of amyloid-beta precursor protein (APP)<sub>669-711</sub>/amyloid-beta (Aβ)<sub>1-42</sub> and Aβ<sub>1-40</sub>/Aβ<sub>1-42</sub> ratios; p-tau181, phosphorylated tau 181; NfL, neurofilament light chain; aSyn/Hb, alpha-synuclein/hemoglobin ratio; MoCA-J, the Japanese version of the Montreal Cognitive Assessment; UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; SCOPA-AUT, the Japanese version of the Scale for Outcomes in Parkinson's disease for Autonomic Symptoms; SAOQ, Self-administered Odor Question; RBDSQ, RBD screening scale; BDI-II, Beck Depression Inventory-Second Edition; ESS, Epworth Sleepiness Scale; PDQ-39, Parkinson's Disease Questionnaire-39; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease